AusDoc website
  • News
  • Opinion
  • Jobs
    Login Join
    AusDoc website
    AusDoc website
    • Login
    • Create an account
    • About Us
    • Advertise
    • Contact us
    • Privacy
    • Terms and Conditions

    Article Type: Specialist Update

    FDA investigates secondary malignancy risk with CAR T-cell therapy

    December 13, 2023

    The TGA is closely watching an overseas investigation of chimeric antigen receptor T-cell therapies after reports of secondary malignancies in treated patients. Last month, the…

    Isthmocele, not prior C-section, lowers IVF success rate: study

    December 1, 2023

    Isthmocele formation after a previous caesarean section — rather than the C-section itself — lowers the odds of a live birth in women undergoing IVF,…

    Colon cancer resection type ‘most important predictor’ of anastomotic leak

    November 24, 2023

    Total colectomy is the most significant risk factor for anastomotic leak following colon cancer resections, putting patients at four times higher risk of the catastrophic…

    Delayed cord clamping ‘best treatment’ for cutting preterm infant mortality

    November 17, 2023

    Preterm infants are 32% less likely to die with delayed versus immediate umbilical cord clamping, according to Australian researchers who say their findings will inform…

    Osimertinib-chemo combo boosts progression-free survival in EGFR-mutated lung cancer: study

    November 14, 2023

    Adding chemotherapy to oral osimertinib in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer prolongs progression-free survival by up to nine months,…

    Offer salpingo-oophorectomy with C-section in BRCA mutation carriers: gynaecologists

    November 10, 2023

    Prophylactic bilateral salpingo-oophorectomy should be offered at time of obstetric-indicated caesarean delivery in women with the BRCA1 or BRCA2 pathogenic variants, say UK gynaecologists. In…

    Add-on biologic a boon for kids with moderate to severe asthma: study

    November 8, 2023

    Fortnightly dupilumab with standard therapy leads to rapid and sustained improvements in asthma control for 6-11 year-olds with moderate to severe type 2 asthma, research…

    COSA’s 50th ASM: Dr Belinda Yeo talks metastatic breast cancer, fertility and AI in oncology

    October 31, 2023

    On Wednesday, hundreds of Australian and overseas doctors will attend the opening of the Clinical Oncology Society of Australia’s 50th Annual Scientific Meeting in Melbourne.…

    Asthma medication use in pregnancy ‘does not impair neurodevelopment in kids’

    October 27, 2023

    Corticosteroids and beta2 agonists are safe to use during pregnancy to manage asthma, say Japanese researchers who found no major impact of anti-asthmatic exposure on…

    New NSCLC standard of care? Perioperative immunotherapy trial improves outcomes

    October 25, 2023

    Perioperative durvalumab in combination with chemotherapy should be considered as a potential new treatment option for resectable non-small cell lung cancer, according to US oncologists.…

    Load More

    Login or join to access the full article

    Login or Join

    Latest Articles

    Loading...
    • Home
    • Articles
    • Jobs
    • More

    Loading...

    New NSCLC standard of care? Perioperative immunotherapy trial improves outcomes

    Report

    There was a problem reporting this post.

    Harassment or bullying behavior
    Contains mature or sensitive content
    Contains misleading or false information
    Contains abusive or derogatory content
    Content that breaches the privacy of other individuals
    Contains spam, fake content or potential malware

    Block Member?

    Please confirm you want to block this member.

    You will no longer be able to:

    • See blocked member's posts
    • Mention this member in posts
    • Message this member
    • Add this member as a connection

    Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

    Report

    You have already reported this .